vs

Side-by-side financial comparison of Victoria's Secret & Co. (VSCO) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

Victoria's Secret & Co. is the larger business by last-quarter revenue ($1.5B vs $961.0M, roughly 1.5× DENTSPLY SIRONA Inc.). Victoria's Secret & Co. runs the higher net margin — -2.5% vs -15.2%, a 12.7% gap on every dollar of revenue. On growth, Victoria's Secret & Co. posted the faster year-over-year revenue change (9.3% vs 6.2%). DENTSPLY SIRONA Inc. produced more free cash flow last quarter ($60.0M vs $-232.0M). Over the past eight quarters, DENTSPLY SIRONA Inc.'s revenue compounded faster (0.4% CAGR vs -15.9%).

Victoria's Secret is an American lingerie, clothing and beauty retailer. Founded in 1977 by Stanford graduate student Roy Raymond and his wife Gaye, the company's five lingerie stores were sold to Les Wexner in 1982. Wexner rapidly expanded into American shopping malls, expanding the company into 350 stores nationally with sales of $1 billion by the early 1990s, when Victoria's Secret became the largest lingerie retailer in the United States.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

VSCO vs XRAY — Head-to-Head

Bigger by revenue
VSCO
VSCO
1.5× larger
VSCO
$1.5B
$961.0M
XRAY
Growing faster (revenue YoY)
VSCO
VSCO
+3.1% gap
VSCO
9.3%
6.2%
XRAY
Higher net margin
VSCO
VSCO
12.7% more per $
VSCO
-2.5%
-15.2%
XRAY
More free cash flow
XRAY
XRAY
$292.0M more FCF
XRAY
$60.0M
$-232.0M
VSCO
Faster 2-yr revenue CAGR
XRAY
XRAY
Annualised
XRAY
0.4%
-15.9%
VSCO

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
VSCO
VSCO
XRAY
XRAY
Revenue
$1.5B
$961.0M
Net Profit
$-37.0M
$-146.0M
Gross Margin
36.4%
46.1%
Operating Margin
-1.3%
-14.5%
Net Margin
-2.5%
-15.2%
Revenue YoY
9.3%
6.2%
Net Profit YoY
33.9%
66.0%
EPS (diluted)
$-0.46
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
VSCO
VSCO
XRAY
XRAY
Q4 25
$1.5B
$961.0M
Q3 25
$1.5B
$904.0M
Q2 25
$1.4B
$936.0M
Q1 25
$2.1B
$879.0M
Q4 24
$1.3B
$905.0M
Q3 24
$1.4B
$951.0M
Q2 24
$1.4B
$984.0M
Q1 24
$2.1B
$953.0M
Net Profit
VSCO
VSCO
XRAY
XRAY
Q4 25
$-37.0M
$-146.0M
Q3 25
$16.0M
$-427.0M
Q2 25
$-2.0M
$-45.0M
Q1 25
$193.0M
$20.0M
Q4 24
$-56.0M
$-430.0M
Q3 24
$32.0M
$-494.0M
Q2 24
$-4.0M
$-4.0M
Q1 24
$180.0M
$18.0M
Gross Margin
VSCO
VSCO
XRAY
XRAY
Q4 25
36.4%
46.1%
Q3 25
35.6%
48.8%
Q2 25
35.0%
52.4%
Q1 25
38.6%
53.0%
Q4 24
34.7%
49.3%
Q3 24
35.4%
52.1%
Q2 24
36.9%
51.9%
Q1 24
39.7%
53.1%
Operating Margin
VSCO
VSCO
XRAY
XRAY
Q4 25
-1.3%
-14.5%
Q3 25
2.8%
-24.1%
Q2 25
1.5%
-13.7%
Q1 25
12.8%
7.2%
Q4 24
-3.5%
-56.2%
Q3 24
4.4%
-48.6%
Q2 24
1.9%
5.1%
Q1 24
12.4%
4.4%
Net Margin
VSCO
VSCO
XRAY
XRAY
Q4 25
-2.5%
-15.2%
Q3 25
1.1%
-47.2%
Q2 25
-0.1%
-4.8%
Q1 25
9.2%
2.3%
Q4 24
-4.2%
-47.5%
Q3 24
2.3%
-51.9%
Q2 24
-0.3%
-0.4%
Q1 24
8.6%
1.9%
EPS (diluted)
VSCO
VSCO
XRAY
XRAY
Q4 25
$-0.46
$-0.74
Q3 25
$0.20
$-2.14
Q2 25
$-0.02
$-0.22
Q1 25
$2.41
$0.10
Q4 24
$-0.71
$-2.09
Q3 24
$0.40
$-2.46
Q2 24
$-0.05
$-0.02
Q1 24
$2.32
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
VSCO
VSCO
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$249.0M
$326.0M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$653.0M
$1.3B
Total Assets
$5.1B
$5.4B
Debt / EquityLower = less leverage
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
VSCO
VSCO
XRAY
XRAY
Q4 25
$249.0M
$326.0M
Q3 25
$188.0M
$363.0M
Q2 25
$138.0M
$359.0M
Q1 25
$227.0M
$398.0M
Q4 24
$161.0M
$272.0M
Q3 24
$169.0M
$296.0M
Q2 24
$105.0M
$279.0M
Q1 24
$270.0M
$291.0M
Total Debt
VSCO
VSCO
XRAY
XRAY
Q4 25
$2.3B
Q3 25
Q2 25
Q1 25
Q4 24
$1.7B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
VSCO
VSCO
XRAY
XRAY
Q4 25
$653.0M
$1.3B
Q3 25
$680.0M
$1.5B
Q2 25
$645.0M
$2.0B
Q1 25
$640.0M
$2.0B
Q4 24
$429.0M
$1.9B
Q3 24
$472.0M
$2.5B
Q2 24
$423.0M
$3.1B
Q1 24
$417.0M
$3.3B
Total Assets
VSCO
VSCO
XRAY
XRAY
Q4 25
$5.1B
$5.4B
Q3 25
$4.8B
$5.7B
Q2 25
$4.6B
$6.1B
Q1 25
$4.5B
$6.0B
Q4 24
$4.9B
$5.8B
Q3 24
$4.6B
$6.6B
Q2 24
$4.4B
$6.9B
Q1 24
$4.6B
$7.1B
Debt / Equity
VSCO
VSCO
XRAY
XRAY
Q4 25
1.70×
Q3 25
Q2 25
Q1 25
Q4 24
0.90×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
VSCO
VSCO
XRAY
XRAY
Operating Cash FlowLast quarter
$-180.0M
$101.0M
Free Cash FlowOCF − Capex
$-232.0M
$60.0M
FCF MarginFCF / Revenue
-15.8%
6.2%
Capex IntensityCapex / Revenue
3.5%
4.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$309.0M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
VSCO
VSCO
XRAY
XRAY
Q4 25
$-180.0M
$101.0M
Q3 25
$156.0M
$79.0M
Q2 25
$-150.0M
$48.0M
Q1 25
$674.0M
$7.0M
Q4 24
$-248.0M
$87.0M
Q3 24
$115.0M
$141.0M
Q2 24
$-116.0M
$208.0M
Q1 24
$589.0M
$25.0M
Free Cash Flow
VSCO
VSCO
XRAY
XRAY
Q4 25
$-232.0M
$60.0M
Q3 25
$88.0M
$40.0M
Q2 25
$-193.0M
$16.0M
Q1 25
$646.0M
$-12.0M
Q4 24
$-299.0M
$36.0M
Q3 24
$55.0M
$98.0M
Q2 24
$-155.0M
$156.0M
Q1 24
$557.0M
$-9.0M
FCF Margin
VSCO
VSCO
XRAY
XRAY
Q4 25
-15.8%
6.2%
Q3 25
6.0%
4.4%
Q2 25
-14.3%
1.7%
Q1 25
30.7%
-1.4%
Q4 24
-22.2%
4.0%
Q3 24
3.9%
10.3%
Q2 24
-11.4%
15.9%
Q1 24
26.7%
-0.9%
Capex Intensity
VSCO
VSCO
XRAY
XRAY
Q4 25
3.5%
4.3%
Q3 25
4.7%
4.3%
Q2 25
3.2%
3.4%
Q1 25
1.3%
2.2%
Q4 24
3.8%
5.6%
Q3 24
4.2%
4.5%
Q2 24
2.9%
5.3%
Q1 24
1.5%
3.6%
Cash Conversion
VSCO
VSCO
XRAY
XRAY
Q4 25
Q3 25
9.75×
Q2 25
Q1 25
3.49×
0.35×
Q4 24
Q3 24
3.59×
Q2 24
Q1 24
3.27×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

VSCO
VSCO

Sales Channel North America Stores$778.0M53%
Sales Channel Directly To Consumer$429.0M29%
Sales Channel International$265.0M18%
Sales Channel Loyalty And Private Label Credit Card$19.0M1%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons